The effects of hyperlipidaemia on graft and patient outcome in renal trasplantation

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 3, 2004, Pages

  Del Castillo, Domingo ^a   Cruzado, Josep M ^b   Díaz, Joan Manel ^c   Beneyto Castelló, Isabel ^d   Lauzurica Valdemoros, Ricardo ^e   Gómez Huertas, Ernesto ^f   Checa Andrés, M Dolores ^g  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Cardiovascular risk; Graft survival; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia; Kidney transplant; Statins

Indexed keywords

ANTILIPEMIC AGENT; CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; CYCLOSPORIN A; HEPATITIS ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GRAFT SURVIVAL; HEMODIALYSIS; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; SURVIVAL RATE;

EID: 3242666237     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1019     Document Type: Article

References (24)

1. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445
2. Gould AL, Roussouw JE, Santanello JC et al. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97: 946-952
3. Bumgardner GL, Wilson GA, Tso PL et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995; 60: 1418-1421
4. Aakhus A, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med 1996; 239: 177-180
5. Aakhus S, Dahl K, Wideroe TE et al. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648-654
6. Roodnat JJ, Mulder PGH, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704-1710
7. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743
8. Dimeny E, Fellstrom B, Larsson E et al. The role of lipoprotein abnormalities in chronic vascular rejection after kidney transplantation. Transplant Proc 1995; 27: 2036
9. Wissing KM, Abramowicz D, Broeders N et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464-472
10. Wanner CH, Quaschning TH, Weingarnter K. Impact of dyslipidaemia in renal transplant recipients. Curr Opin Urol 2000; 10: 77-80
11. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269
12. Dimeny E, Wahlber J, Larsson E et al. Can histopathological findings in early renal biopsies identify patients at risk for chronic vascular rejection. Clin Transplant 1995; 9: 79-84
13. Isoniemi HM, Krogerus L, von Willebran E et al. Histopathological findings well-functioning, long-term renal allografts. Kidney Int 1992; 41: 151-160
14. Massy ZA, Guijarro C, Wiederkehr M et al. Hypertriglyceridaemia predicts graft loss to chronic rejection in renal transplant recipients. J Am Soc Nephrol 1994; 5: 1023-1026
15. Guijarro C, Massy ZA, Kasiske BE. Clinical correlations between renal allograft failure and hyperlipidaemia. Kidney Int 1995; 52 [Suppl 48]: S56-S59
16. Fellström B. Risk factors for and management of posttransplantation cardiovascular disease. Biodrugs 2001; 15: 261-278
17. Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000; 11: 582-588
18. Danovitch GM. Reduction of cardiovascular morbidity in kidney transplant recipients. Curr Opin Organ Transplant 2001; 6: 145-150
19. Artz MA, Boots JMM, Ligtenberg G et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880-1888
20. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med 1995; 333: 621-627
21. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848-1854
22. Holdaas H, Jardine AG, Wheler DC et al. Effect of fluvastatin on acute allograft rejection: a randomised multicenter trial. Kidney Int 2001; 60: 1900-1907
23. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72: 223-227
24. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation. III: The effects of statins. Am J Kidney Dis 2002; 40: 638-643